Chronic kidney disease stage 3
Pro Research Analysisby 
Searched over 200M research papers
Chronic Kidney Disease Stage 3: Insights and Management
Global Prevalence and Diagnosis of Stage 3 CKD
Chronic Kidney Disease (CKD) is a significant global health issue, with stage 3 CKD being particularly prevalent. A systematic review and meta-analysis revealed that the global prevalence of CKD stages 3-5 is approximately 10.6%, with stage 3 alone accounting for a substantial portion of this figure . Despite its prevalence, a large proportion of stage 3 CKD cases remain undiagnosed. The REVEAL-CKD study found that the prevalence of undiagnosed stage 3 CKD is alarmingly high across several countries, including France (95.5%), Germany (84.3%), Italy (77.0%), Japan (92.1%), and the USA (61.6% and 64.3% in two different databases) 49. Factors contributing to undiagnosed CKD include female sex, older age, and lack of comorbid conditions such as diabetes and hypertension .
Cardiovascular and Renal Outcomes in Stage 3 CKD
Patients with stage 3 CKD face increased risks of cardiovascular morbidity and mortality. Studies indicate that the relative risk of cardiovascular events is significantly higher in individuals with stage 3 CKD compared to those without CKD 68. The PREVEND study highlighted that subjects with stage 3 CKD had higher incidence rates of cardiovascular events and a more pronounced decline in estimated glomerular filtration rate (eGFR) compared to those without CKD . Additionally, the risk of all-cause mortality is elevated in stage 3 CKD patients, with mortality rates ranging from 6% over three years to 51% over ten years .
Treatment and Management Strategies
Pharmacologic Interventions
The American College of Physicians (ACP) provides several recommendations for managing stage 3 CKD. They advise against routine screening for CKD in asymptomatic adults without risk factors and recommend against testing for proteinuria in patients already on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II-receptor blockers (ARBs) . For patients with hypertension and stage 3 CKD, the ACP strongly recommends using either ACEIs or ARBs due to their efficacy in managing blood pressure and reducing proteinuria . Additionally, statin therapy is recommended to manage elevated low-density lipoprotein (LDL) levels in these patients .
Traditional Chinese Medicine (TCM)
A multicenter randomized controlled trial investigated the efficacy of Traditional Chinese Medicine (TCM) in treating stage 3 CKD. The study found that TCM, both alone and in combination with benazepril, improved eGFR and hemoglobin levels while reducing proteinuria and urinary albumin/creatinine ratios. The combination therapy also resulted in higher survival rates and fewer side effects compared to benazepril alone .
Urate-Lowering Therapy
The potential benefits of urate-lowering therapy with febuxostat were explored in a randomized trial involving patients with stage 3 CKD and asymptomatic hyperuricemia. The study concluded that febuxostat did not significantly slow the decline in kidney function compared to placebo, although it did reduce the incidence of gouty arthritis .
Self-Management and Support Interventions
The BRIGHT trial aims to evaluate the effectiveness of a self-management intervention for stage 3 CKD patients. This intervention includes an information guidebook, tailored access to local resources, and telephone support. The trial seeks to improve self-management capacity, health-related quality of life, and blood pressure control, potentially offering a cost-effective approach to managing CKD in primary care settings .
Conclusion
Stage 3 CKD is a prevalent and often undiagnosed condition that significantly increases the risk of cardiovascular events and mortality. Effective management strategies, including pharmacologic interventions, traditional medicine, and self-management support, are crucial in mitigating these risks and improving patient outcomes. Enhanced awareness and timely diagnosis are essential to address the global burden of stage 3 CKD.
Sources and full results
Most relevant research papers on this topic
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Febuxostat did not significantly mitigate the decline in kidney function in patients with stage 3 CKD and asymptomatic hyperuricemia compared to placebo.
Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Stages 1 and 2 chronic kidney disease (CKD) have an increased risk of adverse cardiovascular and renal outcomes, and subdividing stage 3 CKD by urinary albumin excretion >30 mg/24 h improves risk stratification.
DOI